Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kymera Therapeutics, Inc.
Age
12–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be 12 to 75 years of age, inclusive, at the time of signing the IAF (informed assent form) and/or ICF (informed consent form).
Must have chronic AD that has been present for at least 3 years (for participants ≥ 18 years of age) or 1 year (for participants \< 18 years of age) before the Screening visit.
Must have an EASI score ≥ 16 at the Screening and Baseline visits.
Must have a vIGA-AD score ≥ 3 (scale of 0 to 4) at the Screening and Baseline visits.
Must have at least 10% BSA of AD involvement at the Screening and Baseline visits.
Must have a weekly average Peak Pruritus NRS value ≥ 4 at the Baseline visit.
Must have a history within the 6 months prior to the Baseline visit of either an inadequate response to, or inability to take, topical medications for the treatment of AD.
Must apply a stable dose of moisturizer at least twice daily for at least 7 consecutive days immediately prior to the Baseline visit. Participants should be willing to continue using moisturizer twice daily during the study.
Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.
Must agree to contraceptive requirements in compliance with the clinical study and local requirements.
You may not be if
Must not have an unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the Investigator in the 4 weeks before the baseline visit.
Must not have other skin conditions, such as contact dermatitis, psoriasis, tinea corporis, or lupus erythematosus, that may interfere with study assessments.
Must not have a clinically relevant history of respiratory, gastrointestinal (GI), renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, ophthalmological, or connective tissue diseases or disorders.
Must not have any surgical or medical procedure planned during participation in the study.
Must not have a history of alcohol or substance abuse within the previous 2 years.
Must not be pregnant or breastfeeding; must not be a woman planning to become pregnant or breastfeed during the study.
Must not have a history of lack of response to any medication targeting interleukin (IL)-4, IL-13, and/or janus kinase (JAK)- signal transducer and activator of transcription (STAT) pathways (e.g. dupilumab, tralokinumab, upadacitinib, abrocitinib) at approved doses after at least 16 weeks of therapy.
Must not have results from clinical laboratory safety tests that are outside the local reference range at Screening.
Must not have been dosed with any investigational drug or device in a clinical study within 8 weeks or 5 half-lives (whichever is longer) of KT-621 administration.
Female participants of childbearing potential must not have a positive or undetermined pregnancy result at the Screening and baseline visits.
Must not have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results.
Must not be taking or have taken any prespecified prohibited therapies within a specific timeframe as evaluated by the Investigator.
Must not have a known sensitivity to any of the components of KT-621.
Must not be a member of the investigational team or his/her immediate family.
